Abstract 282: Biomarkers of Muscle Damage in Patients with Peripheral Artery Disease
Introduction: Peripheral artery disease (PAD), a manifestation of systemic atherosclerosis (fat, plaque deposition and hardening of arterial walls), characterized by blockages of the arteries supplying the legs affects approximately 8 million lives in the United States. The classic symptom of PAD is intermittent claudication (IC), de[[Unable to Display Character: ﬁ]]ned as walking-induced calf pain and gait dysfunction relieved by rest. At the level of the skeletal muscle ischemic injury is manifested as a gradual and characteristic degradation of muscle histology. This injury includes altered metabolic processes, damaged organelles, and compromised bioenergetics in the affected muscle. In this study, we evaluated the hypothesis that Fourier Transform Infrared (FTIR) spectroscopy of human biopsy samples (gastrocnemius muscle) can be used to identify biochemical alterations in PAD muscle and characterize severity of muscle damage.
Method: FTIR spectral profiles were collected from muscle biopsies of the gastrocnemius from 13 patients consisting of 4 controls, 5 claudicating patients, and 4 critical limb ischemia (CLI) patients. Statistical analysis of the data included an analysis of variance, and partial least squares regression (PLRS) to identify significant differences in spectral peaks and correlate them with clinical diagnosis.
Results: When comparing spectral peaks between controls, claudicants, and CLI patients, significant differences (p<.05) were found in the fingerprint region at spectral peaks between wavenumbers 1200-1250 cm-1. These spectral peaks have been attributed to alterations in protein content, lipids, and DNA or phospholipid groups. FTIR spectral biomarkers, of the muscle, also correlated (r=0.91) with clinical diagnosis of PAD.
Conclusion: FTIR spectroscopy was able to characterize the secondary effects of PAD on the gastrocnemius by identifying unique biochemical signatures of diseased PAD skeletal muscle. These signatures can discriminate control from PAD muscle and correlate with the clinical presentation of the PAD patient. FTIR spectroscopy provides novel spectral biomarkers that may complement existing diagnosis and treatment monitoring methods for PAD.
Author Disclosures: K. Cluff: None. H. Mehraein: None. K. Howard: None. P. Koutakis: None. G.P. Casale: None. I.I. Pipinos: None. J. Subbiah: None.
- © 2015 by American Heart Association, Inc.